Friday, February 1, 2013
Theralase Expands Board of Directors with Strong Financing Capabilities
Toronto, Ontario – February 1, 2013 -- Theralase Technologies Inc. (TSX-V: TLT) announced that effective today Mr. Matthew Perraton PFP, FMA, FCSI and Mr. Guy J. Anderson BA, CFP, CIM, FMA, FCSI, MBA have agreed to serve on the company's Board of Directors.
Mr. Perraton and Mr. Anderson join Mr. Donald Moore, Mr. Randy Bruder and Mr. Roger Dumoulin-White on the board and will be instrumental in helping Theralase secure the financing required to fuel Theralase’s growth over the next 5 to 10 years.
Mr. Perraton brings over 13 years of financial experience to Theralase, most recently as a Financial Planner for TD Waterhouse. Prior to his current position, Mr. Perraton held progressively higher positions with BMO Nesbitt Burns and Bank of Nova Scotia.
Mr. Perraton stated that, “I am delighted to join the board at Theralase, as I am absolutely convinced that Theralase is on the right path for shareholder value with both their therapeutic laser technology for healing tissue and their Photo Dynamic Compound (PDC) technology for destroying cancer. Their technology is far superior to anything I have seen on the market and properly financed I see great opportunities for Theralase in the near term”.
Mr. Anderson brings over 16 years of financial experience to Theralase, most recently as a Wealth Management and Personal Finance Advisor with the Investment Planning Counsel. Prior to his current position, Mr. Anderson held progressively higher positions with Franklin Templeton Investments Canada, T.E. Financial and Bank of Nova Scotia.
Mr. Anderson stated that, “I have followed the progress of Theralase over the last 4 to 5 years and have been amazed that the company has been able to advance such cutting-edge technology on a shoe string budget. I join Matt in saying that properly capitalized there is nothing that stands in the way of Theralase’s success. Their technology is not only the best on the market, but their management team has demonstrated an ability to survive in choppy markets and to advance the technology to the point that it is ready to grow in leaps and bounds”.
Roger Dumoulin-White, President and CEO, Theralase Technologies Inc. stated, “I am pleased that Matt and Guy have agreed to serve on our Board of Directors. They both have broad experience in financial management, regulatory compliance and strategic planning and both possess the vision and financial acumen to drive Theralase forward to achieve our full potential. I welcome Matt and Guy to the board and am confident that both will serve the company and the shareholders well during their tenure.”
Mr. Dumoulin-White also stated, “We are all saddened by the loss of our long time board member Mr. John “Jack” Murphy late last year and we would like to take this opportunity to express our profound condolences to Jack’s family. He was a strong member of our team, an insightful director and always a pleasure to work with. His business judgment and knowledge will be sorely missed”.
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information
President & CEO
416-694-7246 ext. 225
Chief Financial Officer
416-694-7246 ext. 224
Chief Scientific Officer
416-694-7246 ext. 242
Director of Investor Relations
416-694-7246 ext. 258